Dutch health technology company Royal Philips has received the US Food and Drug Administration (FDA) 510(k) approval for its new radiotherapy solution, Spectral CT 7500 RT.
The new spectral computed tomography (CT) solution enhances cancer treatment and planning by providing unique tumour visualisation and tissue characterisation.
It allows radiation oncologists to accurately target tumours based on the specific physiological traits of a patient’s tumour.
Also, the new CT solution is designed to minimise the damage to surrounding the healthy tissue and reduce the potential side effects.
Philips said the Spectral CT 7500 RT is the first radiation therapy CT scanner to provide respiratory-gated spectral imaging.
Philips CT global business leader Dan Xu said: “Tumour delineation, beam attenuation, and respiratory motion are critical factors in radiotherapy planning.
“The spectral information provided by Spectral CT 7500 RT enhances tissue characterisation, enabling wider access to highly personalised and precisely targeted treatment for more patients without adding extra steps to current radiotherapy workflows.”
Philips Spectral CT 7500 RT is designed to advance radiation oncology imaging by combining conventional and spectral CT capabilities in a single scan.
It provides radiation oncologists with all the benefits of 4D conventional CT, along with improved visualisation and quantification of spectral CT.
The system also helps radiotherapy departments by reducing the costs of additional scans while enhancing accuracy and treatment plans for more cancer patients.
Philips Spectral CT 7500 RT acquires both true conventional CT and spectral CT information in a single scan and can automatically create the stopping-power ratio (SPR) map.
Also, it produces direct electron density (ED) results with less than 1% deviation to enhance both the dose calculation and accuracy of radiotherapy planning, said the company.
University of Arkansas for Medical Sciences (UAMS) Medical Center (Arkansas, USA) Department of Radiation Oncology Physics director Zhong Su said: “The Spectral CT system provides us with several capabilities that conventional CT does not have.
“It can provide electron density and effective atomic number results, which we can convert to the proton stopping-power ratio.
“And published data shows that the stopping power ratio obtained in this way has fewer uncertainties compared to regular calibration curves, thereby reducing the uncertainty margins during treatment planning.”
